18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the long-term efficacy and safety of two doses of
safinamide (50 and 100 mg/day, p.o), compared to placebo, as add-on therapy in patients with
idiopathic Parkinson's disease with motor fluctuations, who are currently receiving a stable
dose of levodopa.